Global Transthyretin Amyloidosis Treatment Market: Industry Analysis and forecast 2019 – 2027: By Treatment Type,Disease Type, Distribution Channel,and Region.

Global Transthyretin Amyloidosis Treatment Market is expected to reach US$ 6 Bn. at a CAGR of 42.8 during the forecast period 2027. To know about the Research Methodology :- Request Free Sample Report The report study has analyzed the revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis. Amyloidoses, range of protein disorders, are characterized by insoluble extracellular fibril deposits that get deposited in organs and cause organ dysfunction. Transthyretin is one such protein that can cause transthyretin amyloidosis. Treatments of amyloidosis are used to reduce the amyloidosis and limit amyloid protein production. It happens due to various causes like hereditary factors, bone marrow disorder, or even due to some other underlying sickness. The transthyretin amyloidosis treatment market dynamics are thoroughly studied and explained in the MMR report, which helps to understand emerging market trends, drivers, restraints, opportunities, and challenges at the global and regional level for the TTR amyloidosis treatment market globally. The market is likely to experience robust development post the launch of transthyretin therapeutic drugs, primarily because of growing American African population, growing healthcare spending, and accelerating financial growth. On the flip side, lack of information on this condition and insufficiency of advanced diagnostic methods in middle income economies are significant TTR amyloidosis market barriers. According to the American Society of Clinical Oncology report, nearby 4000 people in the US develop amyloidosis yearly and it is usually diagnosed between people aged 50 to 65 years. There are rare cases of people in their late 20 s being detected with amyloidosis. Therefore,with an upsurge in the ageing population, the market for transthyretin (TTR) amyloidosis treatment will also grow. The MMR report covers the segments in the transthyretin amyloidosis treatment market such as treatment type, disease type, and distribution channel. Based on the disease type, hereditary transthyretin amyloidosis (hATTR) segment was valued US$ XX Mn. in 2019 and is expected to reach a value of US$ XX Mn by 2027, with a CAGR of XX.68% during the forecast period. The hATTR is caused by the misfolding of protein monomers resulting from the TTR. Mutations in the gene for TTR normally result in uncertainty of subsequent fibril formation and TTR. Hereditary transthyretin amyloidosis can be sub-classified into polyneuropathy, cardiomyopathy and mixed. North America transthyretin amyloidosis treatment market was valued US$ XX Mn. in 2019 and is expected to reach a value of US$ XX Mn. by 2027, with a CAGR of XX.32% during 2019-2027. This is attributed to an increasing prevalence of amyloidosis between adults and the ageing & growing geriatric population, which is a significant cause for TTR disease. Such as, as per the ASCO Journal study in 2016, around 4,000 people develop amyloidosis yearly in the United States. Europe stood as the second largest in the transthyretin amyloidosis treatment market thanks to the availability of advanced treatment services, a growing need for the better healthcare industry. Almost 60 new cases of TTR amyloidosis are recorded per year in the U.K, and the age-specific occurrence rate is among 5.1 and 12.8 per million yearly. The MMR report also focuses on global major leading industry players of transthyretin amyloidosis treatment market providing information like company profiles, and revenue. Such as, in 2018, Alnylam Pharmaceuticals Company received the United StatesFDA (Food and Drug Administration) support for its ONPATTRO lipid complex injection RNA interference (RNAi) therapeutic - specified for the treatment of the polyneuropathy of hereditary TTR-mediated amyloidosis in adults. The objective of the report is to present a comprehensive analysis of the Global Transthyretin Amyloidosis Treatment Marketincluding all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Global Transthyretin Amyloidosis Treatment Marketdynamics, structure by analyzing the market segments and projects the Global Transthyretin Amyloidosis Treatment Marketsize. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Transthyretin Amyloidosis Treatment Market make the report investor’s guide.

Scope of the Global Transthyretin Amyloidosis Treatment Market: Inquire before buying

Global Transthyretin Amyloidosis Treatment Market, By Treatment Type

• Small molecules treatment • RNAi therapy • Organ transplantation • Others

Global Transthyretin Amyloidosis Treatment Market, By Disease Type

• Hereditary Transthyretin Amyloidosis o Polyneuropathy o Cardiomyopathy o Mixed • Wild Type

Global Transthyretin Amyloidosis Treatment Market, By Distribution Channel

• Hospital Pharmacies • Specialty Pharmacies • Retail Pharmacies • Online Pharmacies

Global Transthyretin Amyloidosis Treatment Market, By Region

• North America o USA o Canada • Europe o UK o France o Germany o Italy o Spain o Norway o Russia • Asia Pacific o China o India o Japan o South Korea o Australia o Malaysia o Indonesia o Vietnam • South America o Mexico o Brazil o Argentina • Middle East and Africa o GCC Countries o South Africa o Nigeria o Egypt

Key players operating in Global Transthyretin Amyloidosis Treatment Market

• Alnylam Pharmaceuticals, Inc. • Pfizer, Inc. • GlaxoSmithKline Plc. • Ionis Pharmaceuticals, Inc. • Eidos Therapeutics • SOM Innovation Biotech, S.L. • Arcturus Therapeutics • Merck & Co. • AstraZeneca plc. • Prothena Corporation plc. • Bellus Health Inc.
Global Transthyretin Amyloidosis Treatment Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Transthyretin Amyloidosis Treatment Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Transthyretin Amyloidosis Treatment Market Analysis and Forecast 6.1. Transthyretin Amyloidosis Treatment Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Transthyretin Amyloidosis Treatment Market Analysis and Forecast, By Disease Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Transthyretin Amyloidosis Treatment Market Value Share Analysis, By Disease Type 7.4. Transthyretin Amyloidosis Treatment Market Size (US$ Bn) Forecast, By Disease Type 7.5. Transthyretin Amyloidosis Treatment Market Analysis, By Disease Type 7.6. Transthyretin Amyloidosis Treatment Market Attractiveness Analysis, By Disease Type 8. Global Transthyretin Amyloidosis Treatment Market Analysis and Forecast, By Treatment Type 8.1. Introduction and Definition 8.2. Key Findings 8.3. Transthyretin Amyloidosis Treatment Market Value Share Analysis, By Treatment Type 8.4. Transthyretin Amyloidosis Treatment Market Size (US$ Bn) Forecast, By Treatment Type 8.5. Transthyretin Amyloidosis Treatment Market Analysis, By Treatment Type 8.6. Transthyretin Amyloidosis Treatment Market Attractiveness Analysis, By Treatment Type 9. Global Transthyretin Amyloidosis Treatment Market Analysis and Forecast, By Distribution Channel 9.1. Introduction and Definition 9.2. Key Findings 9.3. Transthyretin Amyloidosis Treatment Market Value Share Analysis, By Distribution Channel 9.4. Transthyretin Amyloidosis Treatment Market Size (US$ Bn) Forecast, By Distribution Channel 9.5. Transthyretin Amyloidosis Treatment Market Analysis, By Distribution Channel 9.6. Transthyretin Amyloidosis Treatment Market Attractiveness Analysis, By Distribution Channel 10. Global Transthyretin Amyloidosis Treatment Market Analysis, by Region 10.1. Transthyretin Amyloidosis Treatment Market Value Share Analysis, by Region 10.2. Transthyretin Amyloidosis Treatment Market Size (US$ Bn) Forecast, by Region 10.3. Transthyretin Amyloidosis Treatment Market Attractiveness Analysis, by Region 11. North America Transthyretin Amyloidosis Treatment Market Analysis 11.1. Key Findings 11.2. North America Transthyretin Amyloidosis Treatment Market Overview 11.3. North America Transthyretin Amyloidosis Treatment Market Value Share Analysis, By Disease Type 11.4. North America Transthyretin Amyloidosis Treatment Market Forecast, By Disease Type 11.4.1. Hereditary Transthyretin Amyloidosis 11.4.1.1. Polyneuropathy 11.4.1.2. Cardiomyopathy 11.4.1.3. Mixed 11.4.2. Wild Type 11.5. North America Transthyretin Amyloidosis Treatment Market Value Share Analysis, By Treatment Type 11.6. North America Transthyretin Amyloidosis Treatment Market Forecast, By Treatment Type 11.6.1. Small molecules treatment 11.6.2. RNAi therapy 11.6.3. Organ transplantation 11.6.4. Others 11.7. North America Transthyretin Amyloidosis Treatment Market Value Share Analysis, By Distribution Channel 11.8. North America Transthyretin Amyloidosis Treatment Market Forecast, By Distribution Channel 11.8.1. Hospital Pharmacies 11.8.2. Specialty Pharmacies 11.8.3. Retail Pharmacies 11.8.4. Online Pharmacies 11.9. North America Transthyretin Amyloidosis Treatment Market Value Share Analysis, by Country 11.10. North America Transthyretin Amyloidosis Treatment Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Transthyretin Amyloidosis Treatment Market Analysis, by Country 11.12. U.S. Transthyretin Amyloidosis Treatment Market Forecast, By Disease Type 11.12.1. Hereditary Transthyretin Amyloidosis 11.12.1.1. Polyneuropathy 11.12.1.2. Cardiomyopathy 11.12.1.3. Mixed 11.12.2. Wild Type 11.13. U.S. Transthyretin Amyloidosis Treatment Market Forecast, By Treatment Type 11.13.1. Small molecules treatment 11.13.2. RNAi therapy 11.13.3. Organ transplantation 11.13.4. Others 11.14. U.S. Transthyretin Amyloidosis Treatment Market Forecast, By Distribution Channel 11.14.1. Hospital Pharmacies 11.14.2. Specialty Pharmacies 11.14.3. Retail Pharmacies 11.14.4. Online Pharmacies 11.15. Canada Transthyretin Amyloidosis Treatment Market Forecast, By Disease Type 11.15.1. Hereditary Transthyretin Amyloidosis 11.15.1.1. Polyneuropathy 11.15.1.2. Cardiomyopathy 11.15.1.3. Mixed 11.15.2. Wild Type 11.16. Canada Transthyretin Amyloidosis Treatment Market Forecast, By Treatment Type 11.16.1. Small molecules treatment 11.16.2. RNAi therapy 11.16.3. Organ transplantation 11.16.4. Others 11.17. Canada Transthyretin Amyloidosis Treatment Market Forecast, By Distribution Channel 11.17.1. Hospital Pharmacies 11.17.2. Specialty Pharmacies 11.17.3. Retail Pharmacies 11.17.4. Online Pharmacies 11.18. North America Transthyretin Amyloidosis Treatment Market Attractiveness Analysis 11.18.1. By Disease Type 11.18.2. By Treatment Type 11.18.3. By Distribution Channel 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Transthyretin Amyloidosis Treatment Market Analysis 12.1. Key Findings 12.2. Europe Transthyretin Amyloidosis Treatment Market Overview 12.3. Europe Transthyretin Amyloidosis Treatment Market Value Share Analysis, By Disease Type 12.4. Europe Transthyretin Amyloidosis Treatment Market Forecast, By Disease Type 12.4.1. Hereditary Transthyretin Amyloidosis 12.4.1.1. Polyneuropathy 12.4.1.2. Cardiomyopathy 12.4.1.3. Mixed 12.4.2. Wild Type 12.5. Europe Transthyretin Amyloidosis Treatment Market Value Share Analysis, By Treatment Type 12.6. Europe Transthyretin Amyloidosis Treatment Market Forecast, By Treatment Type 12.6.1. Small molecules treatment 12.6.2. RNAi therapy 12.6.3. Organ transplantation 12.6.4. Others 12.7. Europe Transthyretin Amyloidosis Treatment Market Value Share Analysis, By Distribution Channel 12.8. Europe Transthyretin Amyloidosis Treatment Market Forecast, By Distribution Channel 12.8.1. Hospital Pharmacies 12.8.2. Specialty Pharmacies 12.8.3. Retail Pharmacies 12.8.4. Online Pharmacies 12.9. Europe Transthyretin Amyloidosis Treatment Market Value Share Analysis, by Country 12.10. Europe Transthyretin Amyloidosis Treatment Market Forecast, by Country 12.10.1. Germany 12.10.2. UK 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Norway 12.10.7. Russia 12.11. Europe Transthyretin Amyloidosis Treatment Market Analysis, by Country 12.12. Germany Transthyretin Amyloidosis Treatment Market Forecast, By Disease Type 12.12.1. Hereditary Transthyretin Amyloidosis 12.12.1.1. Polyneuropathy 12.12.1.2. Cardiomyopathy 12.12.1.3. Mixed 12.12.2. Wild Type 12.13. Germany Transthyretin Amyloidosis Treatment Market Forecast, By Treatment Type 12.13.1. Small molecules treatment 12.13.2. RNAi therapy 12.13.3. Organ transplantation 12.13.4. Others 12.14. Germany Transthyretin Amyloidosis Treatment Market Forecast, By Distribution Channel 12.14.1. Hospital Pharmacies 12.14.2. Specialty Pharmacies 12.14.3. Retail Pharmacies 12.14.4. Online Pharmacies 12.15. U.K. Transthyretin Amyloidosis Treatment Market Forecast, By Disease Type 12.15.1. Hereditary Transthyretin Amyloidosis 12.15.1.1. Polyneuropathy 12.15.1.2. Cardiomyopathy 12.15.1.3. Mixed 12.15.2. Wild Type 12.16. U.K. Transthyretin Amyloidosis Treatment Market Forecast, By Treatment Type 12.16.1. Small molecules treatment 12.16.2. RNAi therapy 12.16.3. Organ transplantation 12.16.4. Others 12.17. U.K. Transthyretin Amyloidosis Treatment Market Forecast, By Distribution Channel 12.17.1. Hospital Pharmacies 12.17.2. Specialty Pharmacies 12.17.3. Retail Pharmacies 12.17.4. Online Pharmacies 12.18. France Transthyretin Amyloidosis Treatment Market Forecast, By Disease Type 12.18.1. Hereditary Transthyretin Amyloidosis 12.18.1.1. Polyneuropathy 12.18.1.2. Cardiomyopathy 12.18.1.3. Mixed 12.18.2. Wild Type 12.19. France Transthyretin Amyloidosis Treatment Market Forecast, By Treatment Type 12.19.1. Small molecules treatment 12.19.2. RNAi therapy 12.19.3. Organ transplantation 12.19.4. Others 12.20. France Transthyretin Amyloidosis Treatment Market Forecast, By Distribution Channel 12.20.1. Hospital Pharmacies 12.20.2. Specialty Pharmacies 12.20.3. Retail Pharmacies 12.20.4. Online Pharmacies 12.21. Italy Transthyretin Amyloidosis Treatment Market Forecast, By Disease Type 12.21.1. Hereditary Transthyretin Amyloidosis 12.21.1.1. Polyneuropathy 12.21.1.2. Cardiomyopathy 12.21.1.3. Mixed 12.21.2. Wild Type 12.22. Italy Transthyretin Amyloidosis Treatment Market Forecast, By Treatment Type 12.22.1. Small molecules treatment 12.22.2. RNAi therapy 12.22.3. Organ transplantation 12.22.4. Others 12.23. Italy Transthyretin Amyloidosis Treatment Market Forecast, By Distribution Channel 12.23.1. Hospital Pharmacies 12.23.2. Specialty Pharmacies 12.23.3. Retail Pharmacies 12.23.4. Online Pharmacies 12.24. Spain Transthyretin Amyloidosis Treatment Market Forecast, By Disease Type 12.24.1. Hereditary Transthyretin Amyloidosis 12.24.1.1. Polyneuropathy 12.24.1.2. Cardiomyopathy 12.24.1.3. Mixed 12.24.2. Wild Type 12.25. Spain Transthyretin Amyloidosis Treatment Market Forecast, By Treatment Type 12.25.1. Small molecules treatment 12.25.2. RNAi therapy 12.25.3. Organ transplantation 12.25.4. Others 12.26. Spain Transthyretin Amyloidosis Treatment Market Forecast, By Distribution Channel 12.26.1. Hospital Pharmacies 12.26.2. Specialty Pharmacies 12.26.3. Retail Pharmacies 12.26.4. Online Pharmacies 12.27. Norway Transthyretin Amyloidosis Treatment Market Forecast, By Disease Type 12.27.1. Hereditary Transthyretin Amyloidosis 12.27.1.1. Polyneuropathy 12.27.1.2. Cardiomyopathy 12.27.1.3. Mixed 12.27.2. Wild Type 12.28. Norway Transthyretin Amyloidosis Treatment Market Forecast, By Treatment Type 12.28.1. Small molecules treatment 12.28.2. RNAi therapy 12.28.3. Organ transplantation 12.28.4. Others 12.29. Norway Transthyretin Amyloidosis Treatment Market Forecast, By Distribution Channel 12.29.1. Hospital Pharmacies 12.29.2. Specialty Pharmacies 12.29.3. Retail Pharmacies 12.29.4. Online Pharmacies 12.30. Russia Transthyretin Amyloidosis Treatment Market Forecast, By Disease Type 12.30.1. Hereditary Transthyretin Amyloidosis 12.30.1.1. Polyneuropathy 12.30.1.2. Cardiomyopathy 12.30.1.3. Mixed 12.30.2. Wild Type 12.31. Russia Transthyretin Amyloidosis Treatment Market Forecast, By Treatment Type 12.31.1. Small molecules treatment 12.31.2. RNAi therapy 12.31.3. Organ transplantation 12.31.4. Others 12.32. Russia Transthyretin Amyloidosis Treatment Market Forecast, By Distribution Channel 12.32.1. Hospital Pharmacies 12.32.2. Specialty Pharmacies 12.32.3. Retail Pharmacies 12.32.4. Online Pharmacies 12.33. Europe Transthyretin Amyloidosis Treatment Market Attractiveness Analysis 12.33.1. By Disease Type 12.33.2. By Treatment Type 12.33.3. By Distribution Channel 12.34. PEST Analysis 12.35. Key Trends 12.36. Key Developments 13. Asia Pacific Transthyretin Amyloidosis Treatment Market Analysis 13.1. Key Findings 13.2. Asia Pacific Transthyretin Amyloidosis Treatment Market Overview 13.3. Asia Pacific Transthyretin Amyloidosis Treatment Market Value Share Analysis, By Disease Type 13.4. Asia Pacific Transthyretin Amyloidosis Treatment Market Forecast, By Disease Type 13.4.1. Hereditary Transthyretin Amyloidosis 13.4.1.1. Polyneuropathy 13.4.1.2. Cardiomyopathy 13.4.1.3. Mixed 13.4.2. Wild Type 13.5. Asia Pacific Transthyretin Amyloidosis Treatment Market Value Share Analysis, By Treatment Type 13.6. Asia Pacific Transthyretin Amyloidosis Treatment Market Forecast, By Treatment Type 13.6.1. Small molecules treatment 13.6.2. RNAi therapy 13.6.3. Organ transplantation 13.6.4. Others 13.7. Asia Pacific Transthyretin Amyloidosis Treatment Market Value Share Analysis, By Distribution Channel 13.8. Asia Pacific Transthyretin Amyloidosis Treatment Market Forecast, By Distribution Channel 13.8.1. Hospital Pharmacies 13.8.2. Specialty Pharmacies 13.8.3. Retail Pharmacies 13.8.4. Online Pharmacies 13.9. Asia Pacific Transthyretin Amyloidosis Treatment Market Value Share Analysis, by Country 13.10. Asia Pacific Transthyretin Amyloidosis Treatment Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. South Korea 13.10.5. Australia 13.10.6. Malaysia 13.10.7. Indonesia 13.10.8. Vietnam 13.11. Asia Pacific Transthyretin Amyloidosis Treatment Market Analysis, by Country 13.12. China Transthyretin Amyloidosis Treatment Market Forecast, By Disease Type 13.12.1. Hereditary Transthyretin Amyloidosis 13.12.1.1. Polyneuropathy 13.12.1.2. Cardiomyopathy 13.12.1.3. Mixed 13.12.2. Wild Type 13.13. China Transthyretin Amyloidosis Treatment Market Forecast, By Treatment Type 13.13.1. Small molecules treatment 13.13.2. RNAi therapy 13.13.3. Organ transplantation 13.13.4. Others 13.14. China Transthyretin Amyloidosis Treatment Market Forecast, By Distribution Channel 13.14.1. Hospital Pharmacies 13.14.2. Specialty Pharmacies 13.14.3. Retail Pharmacies 13.14.4. Online Pharmacies 13.15. India Transthyretin Amyloidosis Treatment Market Forecast, By Disease Type 13.15.1. Hereditary Transthyretin Amyloidosis 13.15.1.1. Polyneuropathy 13.15.1.2. Cardiomyopathy 13.15.1.3. Mixed 13.15.2. Wild Type 13.16. India Transthyretin Amyloidosis Treatment Market Forecast, By Treatment Type 13.16.1. Small molecules treatment 13.16.2. RNAi therapy 13.16.3. Organ transplantation 13.16.4. Others 13.17. India Transthyretin Amyloidosis Treatment Market Forecast, By Distribution Channel 13.17.1. Hospital Pharmacies 13.17.2. Specialty Pharmacies 13.17.3. Retail Pharmacies 13.17.4. Online Pharmacies 13.18. Japan Transthyretin Amyloidosis Treatment Market Forecast, By Disease Type 13.18.1. Hereditary Transthyretin Amyloidosis 13.18.1.1. Polyneuropathy 13.18.1.2. Cardiomyopathy 13.18.1.3. Mixed 13.18.2. Wild Type 13.19. Japan Transthyretin Amyloidosis Treatment Market Forecast, By Treatment Type 13.19.1. Small molecules treatment 13.19.2. RNAi therapy 13.19.3. Organ transplantation 13.19.4. Others 13.20. Japan Transthyretin Amyloidosis Treatment Market Forecast, By Distribution Channel 13.20.1. Hospital Pharmacies 13.20.2. Specialty Pharmacies 13.20.3. Retail Pharmacies 13.20.4. Online Pharmacies 13.21. South Korea Transthyretin Amyloidosis Treatment Market Forecast, By Disease Type 13.21.1. Hereditary Transthyretin Amyloidosis 13.21.1.1. Polyneuropathy 13.21.1.2. Cardiomyopathy 13.21.1.3. Mixed 13.21.2. Wild Type 13.22. South Korea Transthyretin Amyloidosis Treatment Market Forecast, By Treatment Type 13.22.1. Small molecules treatment 13.22.2. RNAi therapy 13.22.3. Organ transplantation 13.22.4. Others 13.23. South Korea Transthyretin Amyloidosis Treatment Market Forecast, By Distribution Channel 13.23.1. Hospital Pharmacies 13.23.2. Specialty Pharmacies 13.23.3. Retail Pharmacies 13.23.4. Online Pharmacies 13.24. Australia Transthyretin Amyloidosis Treatment Market Forecast, By Disease Type 13.24.1. Hereditary Transthyretin Amyloidosis 13.24.1.1. Polyneuropathy 13.24.1.2. Cardiomyopathy 13.24.1.3. Mixed 13.24.2. Wild Type 13.25. Australia Transthyretin Amyloidosis Treatment Market Forecast, By Treatment Type 13.25.1. Small molecules treatment 13.25.2. RNAi therapy 13.25.3. Organ transplantation 13.25.4. Others 13.26. Australia Transthyretin Amyloidosis Treatment Market Forecast, By Distribution Channel 13.26.1. Hospital Pharmacies 13.26.2. Specialty Pharmacies 13.26.3. Retail Pharmacies 13.26.4. Online Pharmacies 13.27. Malaysia Transthyretin Amyloidosis Treatment Market Forecast, By Disease Type 13.27.1. Hereditary Transthyretin Amyloidosis 13.27.1.1. Polyneuropathy 13.27.1.2. Cardiomyopathy 13.27.1.3. Mixed 13.27.2. Wild Type 13.28. Malaysia Transthyretin Amyloidosis Treatment Market Forecast, By Treatment Type 13.28.1. Small molecules treatment 13.28.2. RNAi therapy 13.28.3. Organ transplantation 13.28.4. Others 13.29. Malaysia Transthyretin Amyloidosis Treatment Market Forecast, By Distribution Channel 13.29.1. Hospital Pharmacies 13.29.2. Specialty Pharmacies 13.29.3. Retail Pharmacies 13.29.4. Online Pharmacies 13.30. Indonesia Transthyretin Amyloidosis Treatment Market Forecast, By Disease Type 13.30.1. Hereditary Transthyretin Amyloidosis 13.30.1.1. Polyneuropathy 13.30.1.2. Cardiomyopathy 13.30.1.3. Mixed 13.30.2. Wild Type 13.31. Indonesia Transthyretin Amyloidosis Treatment Market Forecast, By Treatment Type 13.31.1. Small molecules treatment 13.31.2. RNAi therapy 13.31.3. Organ transplantation 13.31.4. Others 13.32. Indonesia Transthyretin Amyloidosis Treatment Market Forecast, By Distribution Channel 13.32.1. Hospital Pharmacies 13.32.2. Specialty Pharmacies 13.32.3. Retail Pharmacies 13.32.4. Online Pharmacies 13.33. Vietnam Transthyretin Amyloidosis Treatment Market Forecast, By Disease Type 13.33.1. Hereditary Transthyretin Amyloidosis 13.33.1.1. Polyneuropathy 13.33.1.2. Cardiomyopathy 13.33.1.3. Mixed 13.33.2. Wild Type 13.34. Vietnam Transthyretin Amyloidosis Treatment Market Forecast, By Treatment Type 13.34.1. Small molecules treatment 13.34.2. RNAi therapy 13.34.3. Organ transplantation 13.34.4. Others 13.35. Vietnam Transthyretin Amyloidosis Treatment Market Forecast, By Distribution Channel 13.35.1. Hospital Pharmacies 13.35.2. Specialty Pharmacies 13.35.3. Retail Pharmacies 13.35.4. Online Pharmacies 13.36. Asia Pacific Transthyretin Amyloidosis Treatment Market Attractiveness Analysis 13.36.1. By Disease Type 13.36.2. By Treatment Type 13.36.3. By Distribution Channel 13.37. PEST Analysis 13.38. Key Trends 13.39. Key Developments 14. Middle East & Africa Transthyretin Amyloidosis Treatment Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Transthyretin Amyloidosis Treatment Market Overview 14.3. Middle East & Africa Transthyretin Amyloidosis Treatment Market Value Share Analysis, By Disease Type 14.4. Middle East & Africa Transthyretin Amyloidosis Treatment Market Forecast, By Disease Type 14.4.1. Hereditary Transthyretin Amyloidosis 14.4.1.1. Polyneuropathy 14.4.1.2. Cardiomyopathy 14.4.1.3. Mixed 14.4.2. Wild Type 14.5. Middle East & Africa Transthyretin Amyloidosis Treatment Market Value Share Analysis, By Treatment Type 14.6. Middle East & Africa Transthyretin Amyloidosis Treatment Market Forecast, By Treatment Type 14.6.1. Small molecules treatment 14.6.2. RNAi therapy 14.6.3. Organ transplantation 14.6.4. Others 14.7. Middle East & Africa Transthyretin Amyloidosis Treatment Market Value Share Analysis, By Distribution Channel 14.8. Middle East & Africa Transthyretin Amyloidosis Treatment Market Forecast, By Distribution Channel 14.8.1. Hospital Pharmacies 14.8.2. Specialty Pharmacies 14.8.3. Retail Pharmacies 14.8.4. Online Pharmacies 14.9. Middle East & Africa Transthyretin Amyloidosis Treatment Market Value Share Analysis, by Country 14.10. Middle East & Africa Transthyretin Amyloidosis Treatment Market Forecast, by Country 14.10.1. GCC Countries 14.10.2. South Africa 14.10.3. Nigeria 14.10.4. Egypt 14.11. Middle East & Africa Transthyretin Amyloidosis Treatment Market Analysis, by Country 14.12. GCC Transthyretin Amyloidosis Treatment Market Forecast, By Disease Type 14.12.1. Hereditary Transthyretin Amyloidosis 14.12.1.1. Polyneuropathy 14.12.1.2. Cardiomyopathy 14.12.1.3. Mixed 14.12.2. Wild Type 14.13. GCC Transthyretin Amyloidosis Treatment Market Forecast, By Treatment Type 14.13.1. Small molecules treatment 14.13.2. RNAi therapy 14.13.3. Organ transplantation 14.13.4. Others 14.14. GCC Transthyretin Amyloidosis Treatment Market Forecast, By Distribution Channel 14.14.1. Hospital Pharmacies 14.14.2. Specialty Pharmacies 14.14.3. Retail Pharmacies 14.14.4. Online Pharmacies 14.15. South Africa Transthyretin Amyloidosis Treatment Market Forecast, By Disease Type 14.15.1. Hereditary Transthyretin Amyloidosis 14.15.1.1. Polyneuropathy 14.15.1.2. Cardiomyopathy 14.15.1.3. Mixed 14.15.2. Wild Type 14.16. South Africa Transthyretin Amyloidosis Treatment Market Forecast, By Treatment Type 14.16.1. Small molecules treatment 14.16.2. RNAi therapy 14.16.3. Organ transplantation 14.16.4. Others 14.17. South Africa Transthyretin Amyloidosis Treatment Market Forecast, By Distribution Channel 14.17.1. Hospital Pharmacies 14.17.2. Specialty Pharmacies 14.17.3. Retail Pharmacies 14.17.4. Online Pharmacies 14.18. Nigeria Transthyretin Amyloidosis Treatment Market Forecast, By Disease Type 14.18.1. Hereditary Transthyretin Amyloidosis 14.18.1.1. Polyneuropathy 14.18.1.2. Cardiomyopathy 14.18.1.3. Mixed 14.18.2. Wild Type 14.19. Nigeria Transthyretin Amyloidosis Treatment Market Forecast, By Treatment Type 14.19.1. Small molecules treatment 14.19.2. RNAi therapy 14.19.3. Organ transplantation 14.19.4. Others 14.20. Nigeria Transthyretin Amyloidosis Treatment Market Forecast, By Distribution Channel 14.20.1. Hospital Pharmacies 14.20.2. Specialty Pharmacies 14.20.3. Retail Pharmacies 14.20.4. Online Pharmacies 14.21. Egypt Transthyretin Amyloidosis Treatment Market Forecast, By Disease Type 14.21.1. Hereditary Transthyretin Amyloidosis 14.21.1.1. Polyneuropathy 14.21.1.2. Cardiomyopathy 14.21.1.3. Mixed 14.21.2. Wild Type 14.22. Egypt Transthyretin Amyloidosis Treatment Market Forecast, By Treatment Type 14.22.1. Small molecules treatment 14.22.2. RNAi therapy 14.22.3. Organ transplantation 14.22.4. Others 14.23. Egypt Transthyretin Amyloidosis Treatment Market Forecast, By Distribution Channel 14.23.1. Hospital Pharmacies 14.23.2. Specialty Pharmacies 14.23.3. Retail Pharmacies 14.23.4. Online Pharmacies 14.24. Middle East & Africa Transthyretin Amyloidosis Treatment Market Attractiveness Analysis 14.24.1. By Disease Type 14.24.2. By Treatment Type 14.24.3. By Distribution Channel 14.25. PEST Analysis 14.26. Key Trends 14.27. Key Developments 15. South America Transthyretin Amyloidosis Treatment Market Analysis 15.1. Key Findings 15.2. South America Transthyretin Amyloidosis Treatment Market Overview 15.3. South America Transthyretin Amyloidosis Treatment Market Value Share Analysis, By Disease Type 15.4. South America Transthyretin Amyloidosis Treatment Market Forecast, By Disease Type 15.4.1. Hereditary Transthyretin Amyloidosis 15.4.1.1. Polyneuropathy 15.4.1.2. Cardiomyopathy 15.4.1.3. Mixed 15.4.2. Wild Type 15.5. South America Transthyretin Amyloidosis Treatment Market Value Share Analysis, By Treatment Type 15.6. South America Transthyretin Amyloidosis Treatment Market Forecast, By Treatment Type 15.6.1. Small molecules treatment 15.6.2. RNAi therapy 15.6.3. Organ transplantation 15.6.4. Others 15.7. South America Transthyretin Amyloidosis Treatment Market Value Share Analysis, By Distribution Channel 15.8. South America Transthyretin Amyloidosis Treatment Market Forecast, By Distribution Channel 15.8.1. Hospital Pharmacies 15.8.2. Specialty Pharmacies 15.8.3. Retail Pharmacies 15.8.4. Online Pharmacies 15.9. South America Transthyretin Amyloidosis Treatment Market Value Share Analysis, by Country 15.10. South America Transthyretin Amyloidosis Treatment Market Forecast, by Country 15.10.1. Mexico 15.10.2. Brazil 15.10.3. Argentina 15.11. South America Transthyretin Amyloidosis Treatment Market Analysis, by Country 15.12. Brazil Transthyretin Amyloidosis Treatment Market Forecast, By Disease Type 15.12.1. Hereditary Transthyretin Amyloidosis 15.12.1.1. Polyneuropathy 15.12.1.2. Cardiomyopathy 15.12.1.3. Mixed 15.12.2. Wild Type 15.13. Brazil Transthyretin Amyloidosis Treatment Market Forecast, By Treatment Type 15.13.1. Small molecules treatment 15.13.2. RNAi therapy 15.13.3. Organ transplantation 15.13.4. Others 15.14. Brazil Transthyretin Amyloidosis Treatment Market Forecast, By Distribution Channel 15.14.1. Hospital Pharmacies 15.14.2. Specialty Pharmacies 15.14.3. Retail Pharmacies 15.14.4. Online Pharmacies 15.15. Mexico Transthyretin Amyloidosis Treatment Market Forecast, By Disease Type 15.15.1. Hereditary Transthyretin Amyloidosis 15.15.1.1. Polyneuropathy 15.15.1.2. Cardiomyopathy 15.15.1.3. Mixed 15.15.2. Wild Type 15.16. Mexico Transthyretin Amyloidosis Treatment Market Forecast, By Treatment Type 15.16.1. Small molecules treatment 15.16.2. RNAi therapy 15.16.3. Organ transplantation 15.16.4. Others 15.17. Mexico Transthyretin Amyloidosis Treatment Market Forecast, By Distribution Channel 15.17.1. Hospital Pharmacies 15.17.2. Specialty Pharmacies 15.17.3. Retail Pharmacies 15.17.4. Online Pharmacies 15.18. Argentina Transthyretin Amyloidosis Treatment Market Forecast, By Disease Type 15.18.1. Hereditary Transthyretin Amyloidosis 15.18.1.1. Polyneuropathy 15.18.1.2. Cardiomyopathy 15.18.1.3. Mixed 15.18.2. Wild Type 15.19. Argentina Transthyretin Amyloidosis Treatment Market Forecast, By Treatment Type 15.19.1. Small molecules treatment 15.19.2. RNAi therapy 15.19.3. Organ transplantation 15.19.4. Others 15.20. Argentina Transthyretin Amyloidosis Treatment Market Forecast, By Distribution Channel 15.20.1. Hospital Pharmacies 15.20.2. Specialty Pharmacies 15.20.3. Retail Pharmacies 15.20.4. Online Pharmacies 15.21. South America Transthyretin Amyloidosis Treatment Market Attractiveness Analysis 15.21.1. By Disease Type 15.21.2. By Treatment Type 15.21.3. By Distribution Channel 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Alnylam Pharmaceuticals, Inc. 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. Pfizer, Inc. 16.3.3. GlaxoSmithKline Plc. 16.3.4. Ionis Pharmaceuticals, Inc. 16.3.5. Eidos Therapeutics 16.3.6. SOM Innovation Biotech, S.L. 16.3.7. Arcturus Therapeutics 16.3.8. Merck & Co. 16.3.9. AstraZeneca plc. 16.3.10. Prothena Corporation plc. 16.3.11. Bellus Health Inc 17. Primary Key Insights

About This Report

Report ID 70542
Category Healthcare
Published Date August 2020
Updated Date
Contact Us